Compile Data Set for Download or QSAR
Report error Found 454 Enz. Inhib. hit(s) with all data for entry = 204
TargetVascular endothelial growth factor receptor 2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM227802(US10047096, 65 | rac-4-[(2-Fluoro-5-hydroxy-4-meth...)
Affinity DataIC50: 0.246nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2018
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM227931(US10047096, 192 | trans-Ethyl 3-[({4-[(2-fluoro-5-...)
Affinity DataIC50: 0.274nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2018
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM227801(US10047096, 64 | 4-[(2-Fluoro-5-hydroxy-4-methylph...)
Affinity DataIC50: 0.287nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2018
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM227926(US10047096, 187 | 4-[(2-Fluoro-5-hydroxy-4-methylp...)
Affinity DataIC50: 0.325nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2018
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM227794(US10047096, 57 | rac-1-({4-[(2-Fluoro-5-hydroxy-4-...)
Affinity DataIC50: 0.330nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2018
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM227785(US10047096, 48 | 4-[(2-Fluoro-5-hydroxy-4-methylph...)
Affinity DataIC50: 0.363nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2018
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM227814(US10047096, 76 | 4-[(2-Fluoro-5-hydroxy-4-methylph...)
Affinity DataIC50: 0.372nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2018
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM227786(US10047096, 49 | 8-{[Ethyl(methyl)amino]methyl}-4-...)
Affinity DataIC50: 0.388nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2018
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM227902(US10047096, 163 | 4-[(2-Fluoro-5-hydroxy-4-methylp...)
Affinity DataIC50: 0.388nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2018
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM227799(US10047096, 62 | rac-4-[(2-Fluoro-5-hydroxy-4-meth...)
Affinity DataIC50: 0.394nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2018
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM227765(US10047096, 28 | US10047096, 193 | 8-[(Diethylamin...)
Affinity DataIC50: 0.401nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2018
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM227906(US10047096, 167 | 4-[(2-Fluoro-5-hydroxy-4-methylp...)
Affinity DataIC50: 0.407nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2018
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM227930(US10047096, 191 | cis-Ethyl 3-[({4-[(2-fluoro-5-hy...)
Affinity DataIC50: 0.419nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2018
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM227816(US10047096, 78 | 8-{[(1,3-Dihydroxypropan-2-yl)ami...)
Affinity DataIC50: 0.429nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2018
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM227796(US10047096, 59 | 4-[(2-Fluoro-5-hydroxy-4-methylph...)
Affinity DataIC50: 0.432nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2018
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM227768(US10047096, 31 | 8-[(Ethylamino)methyl]-4-[(2-fluo...)
Affinity DataIC50: 0.448nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2018
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM227812(US10047096, 74 | 4-[(2-Fluoro-5-hydroxy-4-methylph...)
Affinity DataIC50: 0.459nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2018
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM227771(US10047096, 34 | US10047096, 226 | 8-[(Cyclopentyl...)
Affinity DataIC50: 0.472nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2018
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM227792(US10047096, 55 | 8-{[Ethyl(2-methoxyethyl)amino]me...)
Affinity DataIC50: 0.473nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2018
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM227812(US10047096, 74 | 4-[(2-Fluoro-5-hydroxy-4-methylph...)
Affinity DataIC50: 0.475nMpH: 7.5 T: 2°CAssay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human PDGFR (amino acids R561-L1106), expres...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2018
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM227786(US10047096, 49 | 8-{[Ethyl(methyl)amino]methyl}-4-...)
Affinity DataIC50: 0.487nMpH: 7.5 T: 2°CAssay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human PDGFR (amino acids R561-L1106), expres...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2018
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM227807(US10047096, 69 | rac-4-[(2-Fluoro-5-hydroxy-4-meth...)
Affinity DataIC50: 0.496nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2018
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM227782(US10047096, 45 | 4-[(2-Fluoro-5-hydroxy-4-methylph...)
Affinity DataIC50: 0.498nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2018
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM227925(US10047096, 186 | 4-[(2-Fluoro-5-hydroxy-4-methylp...)
Affinity DataIC50: 0.503nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2018
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM227929(US10047096, 190 | 4-[(2-Fluoro-5-hydroxy-4-methylp...)
Affinity DataIC50: 0.503nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2018
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM227830(US10047096, 91 | 4-[(2-Fluoro-5-hydroxy-4-methylph...)
Affinity DataIC50: 0.522nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2018
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM227790(US10047096, 53 | 8-{[Butyl(ethyl)amino]methyl}-4-[...)
Affinity DataIC50: 0.525nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2018
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM227795(US10047096, 58 | rac-4-[(2-Fluoro-5-hydroxy-4-meth...)
Affinity DataIC50: 0.548nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2018
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM227934(US10047096, 195 | trans-3-[({4-[(2-Fluoro-5-hydrox...)
Affinity DataIC50: 0.573nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2018
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM227949(US10047096, 210 | 8-{[(3,4-cis-Dihydroxypyrrolidin...)
Affinity DataIC50: 0.578nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2018
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM227783(US10047096, 46 | 4-[(2-Fluoro-5-hydroxy-4-methylph...)
Affinity DataIC50: 0.580nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2018
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM227789(US10047096, 52 | 8-{[Ethyl(2-hydroxyethyl)amino]me...)
Affinity DataIC50: 0.582nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2018
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM227793(US10047096, 56 | 8-[(4,4-Dimethylpiperidin-1-yl)me...)
Affinity DataIC50: 0.595nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2018
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM227947(US10047096, 208 | 4-[(2-Fluoro-5-hydroxy-4-methylp...)
Affinity DataIC50: 0.601nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2018
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM227826(US10047096, 87 | 8-(Aminomethyl)-4-[(2-fluoro-5-hy...)
Affinity DataIC50: 0.613nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2018
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM227909(US10047096, 170 | US10047096, 171 | rac-8-[(3,4-ci...)
Affinity DataIC50: 0.618nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2018
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM227930(US10047096, 191 | cis-Ethyl 3-[({4-[(2-fluoro-5-hy...)
Affinity DataIC50: 0.626nMpH: 7.5 T: 2°CAssay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human PDGFR (amino acids R561-L1106), expres...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2018
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM227807(US10047096, 69 | rac-4-[(2-Fluoro-5-hydroxy-4-meth...)
Affinity DataIC50: 0.647nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2018
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM227807(US10047096, 69 | rac-4-[(2-Fluoro-5-hydroxy-4-meth...)
Affinity DataIC50: 0.670nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2018
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM227928(US10047096, 189 | 8-{[(3,3-Difluorocyclobutyl)amin...)
Affinity DataIC50: 0.677nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2018
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM227800(US10047096, 63 | 8-(Azepan-1-ylmethyl)-4-[(2-fluor...)
Affinity DataIC50: 0.679nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2018
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM227801(US10047096, 64 | 4-[(2-Fluoro-5-hydroxy-4-methylph...)
Affinity DataIC50: 0.680nMpH: 7.5 T: 2°CAssay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human PDGFR (amino acids R561-L1106), expres...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2018
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM227938(US10047096, 199 | 8-({[2-(Dimethylamino)ethyl](eth...)
Affinity DataIC50: 0.689nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2018
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM227933(US10047096, 194 | rac-8-({4-[(2-Fluoro-5-hydroxy-4...)
Affinity DataIC50: 0.692nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2018
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM227813(US10047096, 75 | rac-4-[(2-Fluoro-5-hydroxy-4-meth...)
Affinity DataIC50: 0.706nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2018
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM227962(US10047096, 222 | 8-{[Ethyl(3-hydroxypropyl)amino]...)
Affinity DataIC50: 0.709nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2018
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM227939(US10047096, 200 | 8-{[(2-Aminoethyl)(ethyl)amino]m...)
Affinity DataIC50: 0.714nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2018
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM227939(US10047096, 200 | 8-{[(2-Aminoethyl)(ethyl)amino]m...)
Affinity DataIC50: 0.727nMpH: 7.5 T: 2°CAssay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human PDGFR (amino acids R561-L1106), expres...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2018
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM227940(US10047096, 201 | 4-[(2-Fluoro-5-hydroxy-4-methylp...)
Affinity DataIC50: 0.728nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2018
Entry Details
Go to US Patent

TargetPlatelet-derived growth factor receptor beta(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM227948(US10047096, 209 | 8-{[(2-Aminoethyl)(methyl)amino]...)
Affinity DataIC50: 0.739nMpH: 7.5 T: 2°CAssay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human PDGFR (amino acids R561-L1106), expres...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2018
Entry Details
Go to US Patent

Displayed 1 to 50 (of 454 total ) | Next | Last >>
Jump to: